secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO KEY INTERNATIONAL INC (BKYI)
CIK:        0001019034
Form:       8-K
Filed at:   2026-05-18T12:30:16+00:00
Accession:  0001437749-26-017518
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BIO-key Q1 revenue up 34% to $2.15M, net loss narrows to $(165K); sees Q2 profitability on 65% revenue jump
--------------------------------------------------------------------------------

- Q1 2026 revenue $2.15M (+34% YoY); net loss improved to $(165K) from $(737K) in Q1 2025.
- Gross margin 82%; cash $2.24M at quarter end; EPS $(0.15) post-reverse split.
- Q2 2026 revenue guided ~$2.8M (+65% YoY); expects H1 2026 profitability vs H1 2025 net loss of $(1.9M).
- Secured $1.04M license renewal with foreign bank; defense sales surpassed $2M in trailing twelve months.
- Shares suspended from Nasdaq, now trading OTC under BKYI; company working to return to Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1019034/000143774926017518/0001437749-26-017518-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1019034/000143774926017518/bkyi20260517_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-017518

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer